earnings
confidence high
sentiment positive
materiality 0.75
Halozyme Q2: revenue $221M, GAAP EPS $0.56, Non-GAAP $0.74; raises FY EPS guidance to $2.65-$2.75
HALOZYME THERAPEUTICS, INC.
2023-Q2 EPS reported
$0.84
revenue$383,181,000
- Revenue $221.0M, +45% YoY; GAAP diluted EPS $0.56 vs $0.16 YoY; non-GAAP diluted EPS $0.74 vs $0.53.
- Royalty revenue record $111.7M (+31% YoY), driven by subcutaneous DARZALEX.
- Raised 2023 non-GAAP diluted EPS guidance to $2.65-$2.75 from $2.50-$2.65; revenue guidance $825-$845M.
- FDA approval of VYVGART Hytrulo (argenx) for gMG triggered $33M milestones and royalties.
- Positive Phase 3 data from Roche's SC ocrelizumab and argenx's CIDP trial support pipeline growth.